RCUS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcus Biosciences Inc (RCUS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive developments in hedge fund activity and upcoming clinical updates, the current pre-market price drop, lack of strong trading signals, and mixed analyst ratings suggest a cautious approach. The financial performance shows some growth in revenue but remains unprofitable, and there are no significant catalysts to justify immediate action.
The technical indicators are mixed: MACD is positive and expanding, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but RSI is neutral at 67.687. The stock is trading near a resistance level (R1: 23.094), with limited upside potential in the short term.
Hedge funds are significantly increasing their positions (+186.42% last quarter). Analysts have raised price targets recently, with Wedbush adding the stock to its Best Ideas List ahead of key clinical updates in 2026.
Pre-market price is down by -1.29%. Wells Fargo recently downgraded the stock, citing potential headwinds from data readouts and unclear differentiation. The stock has a 40% chance to decline -4.17% in the next month based on historical patterns.
In Q4 2025, revenue increased by 26.92% YoY to $33M, but the company remains unprofitable with a net loss of $106M (improved by 12.77% YoY). EPS dropped by -13.59% YoY to -0.89, indicating ongoing challenges in achieving profitability.
Analysts are mixed: Wedbush, Citi, and Leerink have raised price targets and maintain Outperform/Buy ratings, but Wells Fargo downgraded the stock to Equal Weight with a reduced price target of $23.
